Inclusion Criteria

• Ability to understand the purpose of the study, provide signed and dated informed consent, and able to comply with all procedures
• Males or females 
• Age ≥ 18 years
• Life expectancy ≥ 12 weeks as judged by the Investigator
• May be on bisphosphonate or denosumab provided it has not been initiated within 14 days of receiving the first administration of MSB0011359C
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry
• Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
• Adequate hematological, hepatic and renal function as defined in the protocol
• Effective contraception for both males and females if the risk of conception exists
• Other protocol-defined criteria could apply

Exclusion Criteria

• Concurrent treatment with non-permitted drugs and other interventions
• Anticancer treatment within 28 days before the start of trial treatment, for example
  • Cyto reductive therapy
  • Radiotherapy (with the exception of palliative bone directed radiotherapy)
  • Immune therapy
  • Cytokine therapy
• Major surgery within 28 days before the start of trial treatment (excluding prior diagnostic biopsy)
• Systemic therapy with immunosuppressive agents within 7 days before the start of trial treatment 
• Use of any investigational drug within 28 days before the start of trial treatment
• Previous malignant disease other than the target malignancy to be investigated in this trial with the exception of
  • Cervical carcinoma in situ and superficial or non invasive bladder cancer (treated with curative intent) within the last 5 years 
  • Basal cell or squamous cell carcinoma in situ within the last 3 years
• Rapidly progressive disease which, in the opinion of the Investigator, may predispose to inability to tolerate treatment or trial procedures
• Active or history of central nervous system metastases, except as in the melanoma-specific CNS criteria listed above
• Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (eg, corneal transplant, hair transplant)
• Other protocol-defined criteria could apply